Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PERK inhibitor HC-5404-FU

The hemifumarate salt form of HC-5404, an orally bioavailable inhibitor of the serine/threonine kinase protein kinase R (PKR)–like endoplasmic reticulum kinase (PERK; eukaryotic translation initiation factor 2-alpha kinase 3; EIF2AK3; PEK) with potential antineoplastic activity. Upon oral administration of PERK inhibitor HC-5404-FU, HC-5404 inhibits the activity of PERK. This prevents the activation of the PERK pathway and inhibits unfolded protein response (UPR) stress adaptation, which may lead to tumor cell apoptosis and the inhibition of tumor growth. PERK, one of the key sensors for the UPR, plays a key role in the response to and resolution of endoplasmic reticulum (ER) stress and also in tumor angiogenesis and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HC 5404 hemifumarate
PERKi HC 5404-FU
Code name:HC 5404-FU
HC-5404 FU
HC-5404-FU
HC5404-FU
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search